Author Affiliations: Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania.
Tuberous sclerosis complex (TSC) is a multisystem hamartomatous disorder that can occur in nearly every tissue in the body but primarily affects the skin, brain, and eye. Major and minor diagnostic criteria for TSC have been established by the Tuberous Sclerosis Consensus Conference in 19981 (eTable 1). A diagnosis of definite TSC is established by the presence of 2 major features or 1 major feature plus 2 minor features. A diagnosis of probable TSC requires the presence of 1 major feature and 1 minor feature, and a diagnosis of possible TSC requires the presence of either 1 major feature or 2 or more minor features.
The most common eye finding of tuberous sclerosis is the retinal astrocytic hamartoma.2 Other features include eyelid angiofibroma, iris atrophy, uveal coloboma, and retinal achromatic patch. The retinal achromatic patch is not clearly described, and this could represent a flat astrocytic hamartoma or retinal pigment epithelial (RPE) “punched-out” depigmentation. The relationship of RPE punched-out depigmentation with TSC is not well recognized. Herein, we analyze the relationship of RPE depigmented lesions with TSC.
The computer-coded records of all patients evaluated on the Ocular Oncology Service at Wills Eye Institute in Philadelphia, Pennsylvania, were reviewed for TSC (eTable 1) or retinal astrocytic hamartoma between July 1974 and November 2010. Each chart was evaluated for patient and tumor features. The affected eye was evaluated for the presence, multiplicity, location, and basal dimension of retinal astrocytic hamartoma(s) and RPE depigmented lesions.
Statistical evaluation was performed to evaluate the relationship of RPE depigmentation with clinical features of TSC using logistic regression analysis (Table). The specific features of RPE lesions were evaluated based on definite vs probable/possible TSC using logistic regression analysis (eTable 2). The demographic and baseline characteristics of the patients were compared using the Fisher exact test, the independent sample t test, or the Wilcoxon test as appropriate. The mean age between groups was compared using the t test. The related number of retinal astrocytic hamartomas per eye and the basal dimensions were compared using the Wilcoxon rank sum test. All proportions were compared using the Fisher exact test. The odds ratios (ORs) were estimated for those factors identified as significant. A multivariate logistic regression analysis using forward stepwise method was performed to further identify the significant factors associated with RPE lesions.
Of 56 patients with definite TSC (23 patients) or probable/possible TSC (33 patients), RPE depigmented lesions were found in 12 patients (12%) (Figures 1 and 2 and eFigure). The clinical features are listed in our Table. Those manifesting RPE lesions demonstrated significant factors of definite TSC (P < .001; OR, 29.3), seizure history (P = .008; OR, 7.8), mental retardation (P = .006; OR, 21.5), cutaneous adenoma sebaceum (P = .008; OR, 7.6), ash leaf macule (P = .002; OR, 10.6), an increased number of retinal astrocytic hamartomas per eye (P < .001; OR, 1.6), and an extramacular location of retinal astrocytic hamartoma (P = .002; OR, 3.2) (Table).
Figure 1. Retinal pigment epithelial (RPE) depigmented lesion in tuberous sclerosis complex (TSC). Pinpoint RPE lesions (arrows) appear as a single lesion (A) or multifocal lesions (B-D), measuring approximately 200 μm. Note the astrocytic hamartoma (AH) in each eye. E and F, Larger RPE lesions (arrows) (E, F) with TSC in eyes with AH are indicated by the arrows.
Figure 2. Fluorescein angiography can assist in detection of retinal pigment epithelial (RPE) depigmented lesion in tuberous sclerosis complex. Clinical photographs (A, C, and E) and corresponding fluorescein angiograms (B, D, and F) depict the often-subtle RPE defects (arrows) of tuberous sclerosis complex. AH indicates astrocytic hamartoma.
The RPE lesions were found in patients at median of 9 years, compared with patients without RPE lesions who were a median of 25 years (Table). The median number of RPE lesions was 1 per eye (range, up to 7 per eye) (eTable 2). The median RPE lesion diameter was 0.5 mm and did not differ between the definite TSC and the probable/possible TSC groups. Of the 38 RPE lesions in 12 eyes, the lesion sector location was most often superonasal (9 lesions [24%]), inferotemporal (8 lesions [21%]), inferonasal (7 lesions [18%]), and superotemporal (5 lesions [13%]) (eTable 2). There were no lesions in the macular region. The anteroposterior location of the RPE lesions was most commonly in the macula to equator (24 lesions [63%]) or equator to ora serrata region (10 lesions [26%]).
RPE depigmented lesions were not clearly identified as a marker of TSC until recently. In 1975, Shelton3 reported 7 patients with TSC and noted that one had “punched-out” depigmented spots in the peripheral retina labeled (presumed incorrectly) as “ocular histoplasmosis.” Others have since recognized these lesions and speculated a relationship to TSC.4,5
In 2001, Rowley and associates5 explored the relationship of RPE “punched-out” lesions with TSC. In a population-based study of 100 patients with TSC, they found retinal hamartomas (44%), RPE punched-out areas (39%), eyelid angiofibromas (39%), and other features. The RPE lesions were all less than 1.5 mm and were located in the retina mid-periphery. Compared with age-matched controls, RPE lesions were significantly associated with TSC (P < .001), similar to our results.
In our clinic-based population, RPE lesions appeared in patients diagnosed at a younger age (median, 9 vs 25 years). Significant findings included a clinical diagnosis of definite (vs probable/possible) TSC, history of seizures or mental retardation, and findings of adenoma sebaceum, ash leaf macule, and specific features of retinal astrocytic hamartomas.
In summary, focal RPE depigmentation is an important finding in TSC and could be helpful in establishing the diagnosis. This often-subtle finding could be overlooked during examination or misconstrued as unrelated RPE defect.
Correspondence: Dr Carol L. Shields, Department of Ocular Oncology, Wills Eye Institute, Thomas Jefferson University, 840 Walnut St, Ste 1440, Philadelphia, PA 19107 (firstname.lastname@example.org).
Author Contributions: Dr C. L. Shields had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: Support for this work was provided by the Eye Tumor Research Foundation, Philadelphia, Pennsylvania (to Drs C. L. Shields and J. A. Shields).
Role of the Sponsor: The sponsors did not participate in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: Statistical analysis was performed by Dr Rishita Nutheti, Hyderabad, India.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.